NCT04454840View on ClinicalTrials.gov

Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2016

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Plasma from healthy young people treatment + Riluzole

Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.

DRUG

Riluzole

The basic treatment is Riluzole 25\~50mg twice daily

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT04454840 - Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter